Medical Journal. Biosimilar drugs will generate savings to the system, but this advantage should not be, in the opinion of Biosim, the spearhead in the consolidation of these drugs in the system. your potential it depends on its progressive integration into the SNS and its assumption as a tool for innovation and long-term improvement.